๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Primary Immune Thrombocytopenia (ITP)
Clinical trial register · China

Primary Immune Thrombocytopenia (ITP) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5 Tianjin 5 Wuhan 3 Nanchang 3 Jinan 2
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5 Tianjin5 Wuhan3 Nanchang3 Jinan2
All 21 locations
Target enrolment
to

Primary Immune Thrombocytopenia (ITP) trials in China

10 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy
NCT07400250Primary Immune Thrombocytopenia (ITP)
Peking Union Medical College Hospital
Phase 2
28
Beijing
2026-04-01
Not yet open
Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP
NCT07189910Primary Immune Thrombocytopenia (ITP)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4
150
Wuhan
2025-12-01
Recruiting
Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial
NCT06992128Primary Immune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
129
Tianjin
2025-05-22
Recruiting
A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
NCT06929299Primary Immune Thrombocytopenia (ITP)
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 1/2
56
Bengbu, Beijing, Tangshan, Zhengzhou, Nanchang, Xiโ€™an, Tianjin
2025-05-12
Recruiting
Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
NCT06880081Primary Immune Thrombocytopenia (ITP)
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 1
12
Guiyang, Nanchang, Jining, Tianjin, Kunming
2025-03-07
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499Primary Immune Thrombocytopenia (ITP)
argenx
Phase 3
69
Beijing, Bengbu, Chengde, Hohhot, Huai'an, Huizhou, Tianjin, Wuhan
2024-10-18
Active, closed
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
NCT05885555Primary Immune Thrombocytopenia (ITP)
Novartis Pharmaceuticals
Phase 2
41
Wuhan, Beijing, Jinan
2023-08-16
Active, closed
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349Primary Immune Thrombocytopenia (ITP)
Novartis Pharmaceuticals
Phase 3
226
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Changzhou, Nanchang
2023-02-03
Recruiting
Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
NCT04518475Primary Immune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China
Phase 4
224
Tianjin
2020-08-10
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/primary-immune-thrombocytopenia-itp

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 10 of those studies listing the condition Primary Immune Thrombocytopenia (ITP).

How many Primary Immune Thrombocytopenia (ITP) trials are recruiting in China?

6 of the 10 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Primary Immune Thrombocytopenia (ITP)), 10 studies
PhaseStudiesRecruitingShare
Phase 23130%
Phase 33230%
Phase 42120%
Phase 11110%
Phase 1/21110%

Most active sponsors

Lead sponsors with the most studies (Primary Immune Thrombocytopenia (ITP))
Lead sponsorStudiesRecruiting
Institute of Hematology & Blood Diseases Hospital, China22
Novartis Pharmaceuticals20
argenx11
Chongqing Peg-Bio Biopharm Co., Ltd.11
Jiangsu BioJeTay Biotechnology Co., Ltd.11
Peking Union Medical College Hospital10
Shandong University11
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.